

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of: Brian R. Dixon, et al.

Serial No.: [to be assigned]

Filed: herewith

For: Substituted 2-Arylimino Heterocycles and Compositions Containing Them, for Use as Progesterone Receptor Binding Agents

BOX PATENT APPLICATION
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

This information disclosure statement is being submitted along with the filing of a divisional patent application.

Applicants wish to cite for the record in the above-identified application the references submitted by Applicants with the Information Disclosure Statements filed on 14 January 2000, 31 August 2000, and 15 November 2000 in related application USSN 09/453,613.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed *before* the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, if any additional fees are due, please charge Deposit Account 13-3372.

Respectfully submitted,



Reg. No. 41,670

Telephone: (203) 812-3964

Date: October 23, 2001

Jerrie L. Chiu
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516